CTRI/2023/04/051819
Recruiting
未知
Effectiveness and impact on quality of life of a combination of trimetazidine with one hemodynamic agent (ß-blocker or Ca-channel blocker), in patients recently diagnosed with stable angina and still symptomatic despite first line hemodynamic therapy: a prospective, international, non-interventional study.
Servier Affaires Médicales0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: I208- Other forms of angina pectoris
- Sponsor
- Servier Affaires Médicales
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1 Male and female recently diagnosed symptomatic stable Angina patients is equals to Patients presenting with typical angina or angina equivalent with evidence of myocardial ischaemia ST segment changes on ECG regional myocardial dysfunction at echocardiography regional perfusion defect etc Canadian Cardiovascular Society class II or III as well as patients with angina at rest vasospastic angina
- •2 Age morethan 18 years old or the age of the majority in the concerned country
- •3 Inclusion of patients into this non interventional study is exclusively determined by the decision of the physician regarding medical meaningfulness and rationale of treatment with the combination under evaluation in the study
- •4 Patient already treated by only one first line antianginal haemodynamic agent beta blocker or Calcium channel blocker according to CCS management guidelines 2019 and still symptomatic within two to four weeks after initiation of this antianginal treatment. At inclusion SAQ 7 Angina Frequency score should be lessthan 60
- •5 Patient for whom the physician intends to prescribe trimetazidine based on her or his daily medical practice in the management of symptomatic Angina pectoris respecting the SmPC in force in the country Such treatment decision must be taken independently from the participation of the patient in the study.
- •Evidence of a personally signed and dated informed consent document indicating that the patient or a legally acceptable representative has been informed of all pertinent aspects of the study.
Exclusion Criteria
- •1 Any contra\-indication to trimetazidine according to SmPC hypersensitivity to the active substance or to any of the excipients Parkinson disease parkinsonian symptoms, tremors, restless leg syndrome and other related movement disorders severe renal impairment creatinine clearance lessthan 30ml per min.
- •2 Patients already treated by trimetazidine before entry into the study.
- •3 Patients needing another antianginal treatment than the combination assessed within the study (one hemodynamic agent beta blocker or Calcium channel blocker with one metabolic agent ie trimetazidine.
- •4 Previous and current acute coronary syndrome (including any unstable angina: angina at rest which lasts more than 20 min and crescendo angina).
- •5 Previous coronary revascularization by CABG or PCI for either acute coronary syndrome or stable ischaemic heart disease.
- •6 Presence of heart failure, left ventricular hypertrophy, valve disease, dilated or hypertrophic cardiomyopathy, myocarditis, pericarditis, endocarditis, chronic arrythmias or other cardiac vascular condition requiring pharmacological treatment.
- •7 Presence of symptomatic anemia.
- •8 Planned revascularization.
- •9 Life expectancy lessthan 1 year.
- •10 Pregnancy or intention to become pregnant or lactating women during the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Study to compare the efficacy and impact on quality of life of two types of repetitive transcranial magnetic stimulation in chronic migraine patientsHealth Condition 1: G437- Chronic migraine without auraCTRI/2024/03/064293Institute of Medical Sciences Banaras Hindu University
Completed
Not Applicable
Effect of quality of life training on self-efficacy hemodialysis patientsEnd stage renal disease treat with hemodialysis.Care involving dialysisIRCT2013061513677N1Vice chancellor for research, Islamic Azad University Bandar abbas Branch90
Active, not recruiting
Phase 1
A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily). - ACCEchronic idiopathic urticariaMedDRA version: 6.1 Level: PT Classification code 10021247EUCTR2006-001449-33-ITSCHERING-PLOUGH600
Withdrawn
Not Applicable
Effectiveness and efficiency on quality of life of an awarenessprogram on sensory processing Issues for adolescents and adults with autism spectrum disorders and a normal or high IQ.NL-OMON37188niversitair Medisch Centrum Groningen40
Recruiting
Not Applicable
Application observation on quality of life and cohabitation problems in patients with the suburethral PVDF band DynaMesh®-SIS (soft)N39.3Stress incontinenceDRKS00033888FEG Textiltechnik Forschungs- und Entwicklungsgesellschaft mbH100